MALT lymphoma

Following completion of treatment, all patients should undergo clinical follow-up to monitor for recurrence, disease progression, and histological transformation. NCCN guidance suggests a complete history, physical examination, and laboratory assessment (and repeat endoscopy for gastric MALT lymphoma) every 3-6 months for 5 years, and then annually thereafter or as clinically indicated.[23]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas [internet publication]. https://www.nccn.org/guidelines/category_1 ​

Patients receiving chemotherapy should be assessed and monitored with CBC, comprehensive metabolic panel (including LFTs), and LDH prior to each treatment cycle. This aids treatment decisions (e.g., dose adjustments of chemotherapeutic agents).